tetano
Editor, Senior Moderator
BMC Infect Dis
. 2021 Dec 7;21(1):1223.
doi: 10.1186/s12879-021-06902-1.
Emergence of SARS-CoV-2 resistance mutations in a patient who received anti-SARS-COV2 spike protein monoclonal antibodies: a case report
Honorine Fenaux[SUP] 1 2 [/SUP], Romain Gueneau[SUP] 3 [/SUP], Amal Chaghouri[SUP] 4 [/SUP], Benoît Henry[SUP] 3 [/SUP], Lina Mouna[SUP] 5 [/SUP], Anne-Marie Roque-Afonso[SUP] 5 [/SUP], Christelle Vauloup-Fellous[SUP] 5 [/SUP]
Affiliations
Abstract
Background: To manage severe or potentially severe cases of CoronaVirus Disease 2019 (COVID-19), therapeutic monoclonal antibodies targeting Spike protein of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) have been designed. It has been noted in vitro that upon exposure to these treatments, mutations could be selected.
Case presentation: We here report the case of an immunosuppressed patient infected with a B.1.1.7 variant, who received a combination of monoclonal antibodies, and subsequently selected mutations K417N, E484K and Q493R on Spike protein of SARS-CoV-2.
Conclusions: Our case raises the importance of monitoring SARS-CoV-2 mutations in patients receiving monoclonal antibodies and having persistent excretion of the virus, in order to offer optimal management of their infection, and strengthen prevention measures to avoid subsequent transmission of these selected variants.
Keywords: Case report; Monoclonal antibodies; Resistance mutations selection; SARS-CoV-2.
. 2021 Dec 7;21(1):1223.
doi: 10.1186/s12879-021-06902-1.
Emergence of SARS-CoV-2 resistance mutations in a patient who received anti-SARS-COV2 spike protein monoclonal antibodies: a case report
Honorine Fenaux[SUP] 1 2 [/SUP], Romain Gueneau[SUP] 3 [/SUP], Amal Chaghouri[SUP] 4 [/SUP], Benoît Henry[SUP] 3 [/SUP], Lina Mouna[SUP] 5 [/SUP], Anne-Marie Roque-Afonso[SUP] 5 [/SUP], Christelle Vauloup-Fellous[SUP] 5 [/SUP]
Affiliations
- PMID: 34876033
- DOI: 10.1186/s12879-021-06902-1
Abstract
Background: To manage severe or potentially severe cases of CoronaVirus Disease 2019 (COVID-19), therapeutic monoclonal antibodies targeting Spike protein of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) have been designed. It has been noted in vitro that upon exposure to these treatments, mutations could be selected.
Case presentation: We here report the case of an immunosuppressed patient infected with a B.1.1.7 variant, who received a combination of monoclonal antibodies, and subsequently selected mutations K417N, E484K and Q493R on Spike protein of SARS-CoV-2.
Conclusions: Our case raises the importance of monitoring SARS-CoV-2 mutations in patients receiving monoclonal antibodies and having persistent excretion of the virus, in order to offer optimal management of their infection, and strengthen prevention measures to avoid subsequent transmission of these selected variants.
Keywords: Case report; Monoclonal antibodies; Resistance mutations selection; SARS-CoV-2.
